MSDC avoids the glitazone as PhIIb insulin sensitiser dances toward partners
This article was originally published in Scrip
Executive Summary
The private US firm Metabolic Solutions Development Company (MSDC) has presented Phase IIb data for its insulin sensitiser drug candidate that it says has a novel metabolic action that should avoid the side-effects that have damaged the glitazone drug class.